{"schema_version":"secwatch.filing_event.v1","accession":"0001517022-25-000027","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.570625+00:00","generated_at":"2026-05-22T04:04:58.107213+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Akebia posts Q1 2025 net income of $6.1M; Vafseo launch generates $12.0M in net product rev","bullets":["Total Q1 2025 net product revenues $55.8M, up 80% YoY; Vafseo contributed $12.0M in first quarter of U.S. launch.","Net income of $6.1M in Q1 2025 versus net loss of $18.0M in Q1 2024; driven by Vafseo and Auryxia sales.","Auryxia net revenues $43.8M (up from $31.0M YoY); market exclusivity lost March 20, 2025 but no ANDA approved.","Cash and equivalents $113.4M as of March 31, 2025, up from $51.9M at Dec 31, 2024, after $50M public offering.","Plan to initiate Phase 3 VALOR trial for vadadustat in non-dialysis CKD patients in H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001517022-25-000027","json":"https://secwatch.observer/filing/0001517022-25-000027.json","markdown":"https://secwatch.observer/filing/0001517022-25-000027.md","text":"https://secwatch.observer/filing/0001517022-25-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000151702225000027/0001517022-25-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000151702225000027/akba-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T04:04:58.107213+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}